1. Coppin C, Porzsolt F, Awa A et al. (2005) Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev CD001425
2. Linehan WM, Grubb RL, Coleman JA et al. (2005) The genetic basis of cancer of kidney cancer: implications for gene-specific clinical management. BJU Int 95(2): 2–7
3. Merseburger AS, Hennenlotter J, Simon P et al. (2005) Membranous expression and prognostic implications of epidermal growth factor receptor protein in human renal cell cancer. Anticancer Res 25: 1901–1907
4. Hennenlotter J, Ohneseit PA, Simon P et al. (2008) PTEN and p27Kip1 are not downregulated in the majority of renal cell carcinomas - implications for Akt activation. Oncol Rep 19: 1141–1147
5. Awada A, Hendlisz A, Gil T et al. (2005) Phase I safety and pharmacokinetics of BAY 43–9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 92: 1855–1861